Treatment for new liver spread from colon cancer recurrence
Part of Cancer, Digestive system clinical trials.
This Phase 3 trial studies a treatment approach for people whose colorectal cancer has come back in the liver within 12 months and can be treated with local procedures. It aims to see whether the study treatment can improve outcomes compared with standard care for people with a limited number of liver tumors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be older than 18 years
- Have a good overall health status (ECOG 0–2 and ASA 1–3)
- Have colon cancer proven by a tissue test, with liver spread treated locally before
- Have a new recurrence in the liver within the last 12 months, with up to 5 new liver tumors
- The new liver tumors must be treatable by a procedure that removes or destroys them, and you cannot have disease outside the liver
- Cannot have MSI/dMMR tumor type, major liver problems (like portal hypertension/unsafe clotting/ascites), or an uncontrolled infection
- You must not have had chemotherapy or immunotherapy in the last 6 weeks, be able to consent, and have adequate blood/organ function
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 trial tests a treatment approach for colorectal cancer that cannot be removed with surgery at first but has spread only to the liver. It is intended for people whose tumor is RAS/BRAF “wild-type” and who are well enough to do daily activities, to see if the treatment can control the cancer better.
This Phase 3 trial tests whether an added “maintenance” treatment after liver surgery can help prevent colorectal cancer from coming back. It is only for people whose blood test (ctDNA) still shows signs of cancer after their operation.
This trial tests a combination of treatments for people with colorectal cancer that has spread to the liver and cannot be removed by surgery. It uses an oncolytic virus (which infects and kills cancer cells) along with radiation, chemotherapy, targeted therapy, and immunotherapy to try to shrink the liver tumors.
This trial tests whether adding two targeted drugs (serplulimab and bevacizumab) to standard chemotherapy before surgery can improve outcomes for people with colorectal cancer that has spread to the liver. It is for those whose cancer has certain genetic features and is considered resectable.
This trial tests a combination of low-dose radiation, chemotherapy, and immunotherapy for people with colorectal cancer that has spread only to the liver. The goal is to see if this approach can shrink tumors and improve outcomes.
This trial tests giving patients a type of chemotherapy called FOLFIRI after they have had surgery to remove colorectal cancer that spread to the liver. The goal is to see if this additional treatment helps prevent the cancer from coming back, for patients who could not have a different chemotherapy before surgery.
Hear when a new Colorectal cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.